Research Article

Biomaterial-Based Delivery of Bioactive Compounds for Psoriasis Management: Natural Products, Polymeric Systems, and Emerging Therapeutic Strategies

Authors

  • Natalja Osintsev * Fraunhofer-Institut für Holzforschung Wilhelm-Klauditz-Institut WKI Bienroder Weg 54 E, 38108 Brunswick (Braunschweig), Germany.

https://doi.org/10.48313/bic.vi.81

Abstract

Psoriasis is a chronic immune-mediated inflammatory skin disorder characterized by abnormal Keratinocyte proliferation, persistent inflammation, oxidative stress, and disruption of the skin barrier. Although conventional topical and systemic therapies can effectively control disease activity, their clinical use may be limited by adverse effects, inadequate skin penetration, systemic exposure, and incomplete long-term disease control. Bioactive compounds derived from natural sources have attracted considerable interest because of their anti-inflammatory, antioxidant, immunomodulatory, and antiproliferative activities. However, poor aqueous solubility, chemical instability, low bioavailability, and limited penetration into diseased skin frequently restrict their therapeutic application. Biomaterial-based delivery systems provide opportunities to overcome these limitations by improving compound stability, skin retention, controlled release, and localized delivery. This review summarizes the therapeutic potential of natural bioactive compounds for psoriasis and discusses the role of polymeric biomaterials, hydrogels, nanoparticles, nanostructured carriers, and stimuli-responsive systems in their topical delivery. Particular attention is given to the relationship between biomaterial properties and the pathological characteristics of psoriatic skin, as well as preclinical and emerging clinical evidence. Current challenges related to safety, reproducibility, scalability, regulatory requirements, and clinical translation are also discussed. Finally, emerging strategies involving multifunctional, biomimetic, personalized, and intelligent delivery platforms are highlighted as potential directions for future psoriasis therapy.

Keywords

Psoriasis Bioactive compounds Biomaterials Hydrogels Nanocarriers Stimuli-responsive systems Drug delivery
References (47)
  1. [1] Liu, L., Wang, R., Peng, Y., Chen, J., & Yu, C. (2026). Global psoriasis burden and forecasts to 2050. JAMA dermatology, 162(2), 201–203. https://doi.org/10.1001/jamadermatol.2025.4572

  2. [2] Fatani, M. I., Binamer, Y., Alessa, D., Almudaiheem, H. Y., Alajlan, M. A., Hamadah, I., ... & Eshmawi, M. T. (2026). Practical Saudi guidelines on management of moderate-to-severe psoriasis: 2026 update. Journal of dermatological treatment, 37(1), 2724623. https://doi.org/10.1080/09546634.2026.2724623

  3. [3] Maurelli, M., Danese, A., Gisondi, P., & Girolomoni, G. (2026). Biosimilars for chronic plaque psoriasis: A 2026 update. Expert review of clinical pharmacology, 19(5), 447–455. https://doi.org/10.1080/17512433.2026.2667342

  4. [4] Hu, H., Ma, Z., Zhang, Z., Chen, Y., Hu, K., Zhang, P., & Liu, J. (2026). Nanotechnology advances for psoriasis treatment and future prospects. Discover nano, 21(1), 122. https://doi.org/10.1186/s11671-026-04569-8

  5. [5] Masson Regnault, M., Brenaut, E., Marniquet, M. E., Berthault, C., Canoen, L., Marcombes, C., ... & Ouakrat, R. (2026). French guidelines on systemic treatments for moderate‐to‐severe psoriasis in adults: Update 2025. Journal of the European academy of dermatology and venereology, 40(6), 963-979. https://doi.org/10.1111/jdv.70263

Article Metrics

How to Cite

Osintsev , N. . (2026). Biomaterial-Based Delivery of Bioactive Compounds for Psoriasis Management: Natural Products, Polymeric Systems, and Emerging Therapeutic Strategies. Biocompounds, 3(4), 245-270. https://doi.org/10.48313/bic.vi.81

Similar Articles

1-10 of 49

You may also start an advanced similarity search for this article.